CardieX (ASX:CDX) - CEO & Managing Director, Craig Cooper
CEO & Managing Director, Craig Cooper
Source: Craig Cooper
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology
  • This technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis
  • The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure
  • The grant of the European patent follows on from similar patents already granted in the U.S. and Japan in 2016
  • CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents

CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.

The SphygmoCor technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis.

It has more than 4500 installations worldwide and is used by major pharmaceutical companies and research institutions such as The Mayo Clinic, Stanford University, and Johns Hopkins.

The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure and waveform.

This patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease.

The granting of the European patent follows on from similar patents already granted in the United States and Japan in 2016.

“We are very pleased to be granted this new patent to protect our IP in Europe,” CEO and Managing Director Craig Cooper said.

“Of great significance is the findings of the examining officers from the EPO, which were similar to the findings we received from examiners in the U.S. in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology,” he added.

CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents at 2:00 pm AEST.

CDX by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…